Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Seres Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 4 insiders, $2.23K in total
- Insiders trading
- 4
- Net value
- −$2.23K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Seres Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Brady Kelly | See Remarks | 8,679 | Aug 18, 2026 | 4 |
| Shaff Eric D. | Director | 12,499 | Aug 18, 2026 | 5 |
| Henn Matthew R. | See Remarks | 7,995 | Aug 18, 2026 | 7 |
| DesRosier Thomas | See Remarks | 8,117 | Aug 18, 2026 | 6 |
| Graves Kurt | Director | – | Jul 10, 2026 | 1 |
| Kender Richard N | See Remarks | 63,492 | Jul 10, 2026 | 2 |
| Thorell Marella | See Remarks | – | Jul 10, 2026 | 2 |
| Fraser Claire | Director | – | Jul 10, 2026 | 1 |
| Dere Willard H | Director | 31,746 | Jul 10, 2026 | 1 |
| Ausiello Dennis A | Director | – | Jul 10, 2026 | 2 |
| Rosiello Robert L. | Director | – | Jul 10, 2026 | 2 |
| Berenson Stephen | Director | – | Jul 10, 2026 | 2 |
| Young Teresa L. | See Remarks | 8,557 | Feb 18, 2026 | 3 |
| Biondi Paul | Director | 47,619 | Apr 11, 2025 | 0 |
| von Moltke Lisa | See Remarks | 39,875 | Feb 19, 2025 | 0 |
| Woerle Hans-Juergen | Director | – | Feb 6, 2025 | 0 |
| Ege David S. | See Remarks | 77,575 | Aug 19, 2024 | 0 |
| Arkowitz David | Chief Financial Officer | 182,442 | Feb 16, 2024 | 0 |
| Cloghessy Paula | See Remarks | 45,684 | Oct 31, 2023 | 0 |
| Behar Gregory | Director | – | Jun 23, 2023 | 0 |
| Afeyan Noubar | 10% Owner | 5,825,495Indirect | Jul 7, 2022 | 0 |
| Flagship Pioneering, LLC | 10% Owner | 5,825,495Indirect | Jul 7, 2022 | 0 |
| Nutritional Health LTP Fund General Partner LLC | 10% Owner | 5,825,495Indirect | Jul 7, 2022 | 0 |
| Nutritional Health LTP Fund, L.P. | 10% Owner | 5,825,495Indirect | Jul 7, 2022 | 0 |
| Zausner Meryl | Director | 31,746 | Jul 6, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 17, 2024 (view filing) | May 15 | 2 days | Ege David S.See Remarks | SSale | −1.09K | $0.94 | −$1.02K | −1.4%75.7K after | 10b5-1 |
| May 17, 2024 (view filing) | May 15 | 2 days | DesRosier ThomasChief Legal Officer and EVP | SSale | −843 | $0.94 | −$792.42 | −0.7%122.4K after | 10b5-1 |
| Feb 16, 2024 (view filing) | Feb 16 | Same day | DesRosier ThomasChief Legal Officer and EVP | SSale | −3.94K | $1.08 | −$4.25K | −3.2%120.6K after | 10b5-1 |
| Feb 16, 2024 (view filing) | Feb 16 | Same day | Shaff Eric D.CEO and President | SSale | −11.5K | $1.08 | −$12.5K | −7.9%135.3K after | 10b5-1 |
| Feb 16, 2024 (view filing) | Feb 16 | Same day | Henn Matthew R.See Remarks | SSale | −4.17K | $1.08 | −$4.50K | −6.2%63.4K after | 10b5-1 |
| Feb 16, 2024 (view filing) | Feb 16 | Same day | Young Teresa L.See Remarks | SSale | −3.37K | $1.08 | −$3.64K | −17.7%15.7K after | 10b5-1 |
| Feb 16, 2024 (view filing) | Feb 16 | Same day | von Moltke LisaSee Remarks | SSale | −4.40K | $1.08 | −$4.75K | −20.6%17.0K after | 10b5-1 |
| Feb 16, 2024 (view filing) | Feb 16 | Same day | Ege David S.See Remarks | SSale | −5.01K | $1.08 | −$5.41K | −6.4%73.9K after | 10b5-1 |
| Feb 16, 2024 (view filing) | Feb 16 | Same day | Arkowitz DavidChief Financial Officer | SSale | −3.94K | $1.08 | −$4.25K | −2.1%182.4K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 30 | 1 day | Cloghessy PaulaSee Remarks | SSale | −2.90K | $1.35 | −$3.92K | −6.0%45.7K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 30 | 1 day | Shaff Eric D.CEO and President | SSale | −8.55K | $1.35 | −$11.5K | −6.9%115.6K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 30 | 1 day | Young Teresa L.See Remarks | SSale | −2.91K | $1.35 | −$3.92K | −25.6%8.45K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 30 | 1 day | Arkowitz DavidChief Financial Officer | SSale | −4.07K | $1.35 | −$5.49K | −2.3%175.8K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 30 | 1 day | DesRosier ThomasChief Legal Officer and EVP | SSale | −4.16K | $1.35 | −$5.61K | −3.5%113.9K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 30 | 1 day | Ege David S.See Remarks | SSale | −4.07K | $1.35 | −$5.49K | −5.7%67.0K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 30 | 1 day | von Moltke LisaSee Remarks | SSale | −4.23K | $1.35 | −$5.71K | −30.8%9.51K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 30 | 1 day | Henn Matthew R.See Remarks | SSale | −3.89K | $1.35 | −$5.25K | −6.5%56.4K after | 10b5-1 |
| May 1, 2023 (view filing) | Apr 28 | 3 days | Ege David S.See Remarks | SSale | −7.04K | $5.19 | −$36.5K | −10.5%59.7K after | |
| Oct 31, 2022 (view filing) | Oct 31 | Same day | Ege David S.See Remarks | SSale | −5.01K | $7.93 | −$39.7K | −9.7%46.7K after | |
| Jul 7, 2022 (view filing)5:00 PM ET | Jul 5 | 2 days | Afeyan Noubar and 3 others10% Owner | PPurchase | +8.74M | $3.15 | +$27.5M | New position5.83M after | 2 lots |